Disease-A-Month
Volume 52, Issue 2 , Pages 55-144 , February 2006

Metabolic Syndrome and Prediabetes

References 

  1. Reaven GM . Banting lecture 1988. Role of insulin resistance in human disease . Diabetes . 1988;37:1595–1607
  2. Kahn R , Buse J , Ferrannini E , et al.   The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes . Diabetes Care . 2005;28:2289–2304
  3. Prevention. CfDCa. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2005.
  4. Hogan P , Dall T , Nikolov P . Economic costs of diabetes in the US in 2002 . Diabetes Care . 2003;26:917–932
  5. Alberti KG , Zimmet PZ . Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation . Diabetes Med . 1998;15:539–553
  6. World Health Organization . Definition, Diagnosis, and Classification of Diabetes Mellitus and its Complications (report of a WHO Consultation) . 1999;
  7. Balkau B , Charles MA  European Group for the Study of Insulin Resistance (EGIR) . Comment on the provisional report from the WHO consultation . Diabetes Med . 1999;16:442–443
  8. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults . Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) . JAMA . 2001;285:2486–2497
  9. Grundy SM , Cleeman JI , Daniels SR , et al.   Diagnosis and management of the metabolic syndrome (an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement) . Circulation . 2005;112:2735–2752
  10. Genuth S , Alberti KG , Bennett P , et al.   Follow-up report on the diagnosis of diabetes mellitus . Diabetes Care . 2003;26:3160–3167
  11. Einhorn D , Reaven GM , Cobin RH , et al.   American College of Endocrinology position statement on the insulin resistance syndrome . Endocr Pract . 2003;9:237–252
  12. Alberti KG , Zimmet P , Shaw J . The metabolic syndrome—a new worldwide definition . Lancet . 2005;366:1059–1062
  13. Ford ES , Giles WH , Dietz WH . Prevalence of the metabolic syndrome among US adults (findings from the third National Health and Nutrition Examination Survey) . JAMA . 2002;287:356–359
  14. Alexander CM , Landsman PB , Teutsch SM , et al.   NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older . Diabetes . 2003;52:1210–1214
  15. Meigs JB , Wilson PW , Nathan DM , et al.   Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies . Diabetes . 2003;52:2160–2167
  16. Scuteri A , Najjar SS , Morrell CH , et al.   The metabolic syndrome in older individuals: prevalence and prediction of cardiovascular events: the Cardiovascular Health Study . Diabetes Care . 2005;28:882–887
  17. Hanley AJ , Wagenknecht LE , D’Agostino RB , et al.   Identification of subjects with insulin resistance and beta-cell dysfunction using alternative definitions of the metabolic syndrome . Diabetes . 2003;52:2740–2747
  18. Ford ES , Abbasi F , Reaven GM . Prevalence of insulin resistance and the metabolic syndrome with alternative definitions of impaired fasting glucose . Atherosclerosis . 2005;181:143–148
  19. Ford ES . Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S . Diabetes Care . 2005;28:2745–2749
  20. Adams RJ , Appleton S , Wilson DH , et al.   Population comparison of two clinical approaches to the metabolic syndrome (implications of the new International Diabetes Federation consensus definition) . Diabetes Care . 2005;28:2777–2779
  21. Cook S , Weitzman M , Auinger P , et al.   Prevalence of a metabolic syndrome phenotype in adolescents (findings from the third National Health and Nutrition Examination Survey, 1988-1994) . Arch Pediatr Adolesc Med . 2003;157:821–827
  22. de Ferranti SD , Gauvreau K , Ludwig DS , et al.   Prevalence of the metabolic syndrome in American adolescents (findings from the Third National Health and Nutrition Examination Survey) . Circulation . 2004;110:2494–2497
  23. Braunschweig CL , Gomez S , Liang H , et al.   Obesity and risk factors for the metabolic syndrome among low-income, urban, African American schoolchildren (the rule rather than the exception?) . Am J Clin Nutr . 2005;81:970–975
  24. Pande M CMD , Lopez C , Fogelfeld L . Metabolic Syndrome Factors in Hispanic Adolescents (Association with Atherosclerosis Markers) . 2004; American Diabetes Association, 64th Annual Meeting, 1028-P
  25. Flegal KM , Carroll MD , Ogden CL , et al.   Prevalence and trends in obesity among US adults, 1999-2000 . JAMA . 2002;288:1723–1727
  26. Hedley AA , Ogden CL , Johnson CL , et al.   Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002 . JAMA . 2004;291:2847–2850
  27. Park YW , Zhu S , Palaniappan L , et al.   The metabolic syndrome (prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994) . Arch Intern Med . 2003;163:427–436
  28. Dallongeville J , Cottel D , Ferrieres J , et al.   Household income is associated with the risk of metabolic syndrome in a sex-specific manner . Diabetes Care . 2005;28:409–415
  29. Ford ES , Kohl HW , Mokdad AH , et al.   Sedentary behavior, physical activity, and the metabolic syndrome among U.S. adults . Obes Res . 2005;13:608–614
  30. Ekelund U , Brage S , Franks PW , et al.   Physical activity energy expenditure predicts progression toward the metabolic syndrome independently of aerobic fitness in middle-aged healthy Caucasians (the Medical Research Council Ely Study) . Diabetes Care . 2005;28:1195–1200
  31. Camargo MD PM, Lopez C, Fogelfeld L. Social and behavioral factors are associated with Metabolic Syndrome Components in Hispanic Adolescents. American Diabetes Association, 64th Annual Meeting, 2004. 1029-P.
  32. Troxel WM , Matthews KA , Gallo LC , et al.   Marital quality and occurrence of the metabolic syndrome in women . Arch Intern Med . 2005;165:1022–1027
  33. Orchard TJ , Temprosa M , Goldberg R , et al.   The effect of metformin and intensive lifestyle intervention on the metabolic syndrome (the Diabetes Prevention Program randomized trial) . Ann Intern Med . 2005;142:611–619
  34. Lemieux I , Pascot A , Couillard C , et al.   Hypertriglyceridemic waist (a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men?) . Circulation . 2000;102:179–184
  35. Carr DB , Utzschneider KM , Hull RL , et al.   Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome . Diabetes . 2004;53:2087–2094
  36. Doll S , Paccaud F , Bovet P , et al.   Body mass index, abdominal adiposity and blood pressure (consistency of their association across developing and developed countries) . Int J Obes Relat Metab Disord . 2002;26:48–57
  37. Rexrode KM , Carey VJ , Hennekens CH , et al.   Abdominal adiposity and coronary heart disease in women . JAMA . 1998;280:1843–1848
  38. Rexrode KM , Buring JE , Manson JE . Abdominal and total adiposity and risk of coronary heart disease in men . Int J Obes Relat Metab Disord . 2001;25:1047–1056
  39. Folsom AR , Kushi LH , Anderson KE , et al.   Associations of general and abdominal obesity with multiple health outcomes in older women (the Iowa Women’s Health Study) . Arch Intern Med . 2000;160:2117–2128
  40. Bergman RN , Van Citters GW , Mittelman SD , et al.   Central role of the adipocyte in the metabolic syndrome . J Investig Med . 2001;49:119–126
  41. Shulman GI . Cellular mechanisms of insulin resistance . J Clin Invest . 2000;106:171–176
  42. Griffin ME , Marcucci MJ , Cline GW , et al.   Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade . Diabetes . 1999;48:1270–1274
  43. Dresner A , Laurent D , Marcucci M , et al.   Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity . J Clin Invest . 1999;103:253–259
  44. Boden G , Chen X . Effects of fat on glucose uptake and utilization in patients with non-insulin-dependent diabetes . J Clin Invest . 1995;96:1261–1268
  45. Boden G , Chen X , Rosner J , et al.   Effects of a 48-h fat infusion on insulin secretion and glucose utilization . Diabetes . 1995;44:1239–1242
  46. Petersen KF , Shulman GI . Pathogenesis of skeletal muscle insulin resistance in type 2 diabetes mellitus . Am J Cardiol . 2002;90:11G–18G
  47. Petersen KF , Shulman GI . Cellular mechanism of insulin resistance in skeletal muscle . J R Soc Med . 2002;95(suppl 42):8–13
  48. Yu C , Chen Y , Cline GW , et al.   Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle . J Biol Chem . 2002;277:50230–50236
  49. Ginsberg HN . Insulin resistance and cardiovascular disease . J Clin Invest . 2000;106:453–458
  50. Ginsberg HN , Stalenhoef AF . The metabolic syndrome (targeting dyslipidaemia to reduce coronary risk) . J Cardiovasc Risk . 2003;10:121–128
  51. Grundy SM . Metabolic complications of obesity . Endocrine . 2000;13:155–165
  52. Katsuki A , Sumida Y , Urakawa H , et al.   Increased visceral fat and serum levels of triglyceride are associated with insulin resistance in Japanese metabolically obese, normal weight subjects with normal glucose tolerance . Diabetes Care . 2003;26:2341–2344
  53. Carr MC , Hokanson JE , Deeb SS , et al.   A hepatic lipase gene promoter polymorphism attenuates the increase in hepatic lipase activity with increasing intra-abdominal fat in women . Arterioscler Thromb Vasc Biol . 1999;19:2701–2707
  54. Pascot A , Despres JP , Lemieux I , et al.   Contribution of visceral obesity to the deterioration of the metabolic risk profile in men with impaired glucose tolerance . Diabetologia . 2000;43:1126–1135
  55. Pascot A , Lemieux I , Prud’homme D , et al.   Reduced HDL particle size as an additional feature of the atherogenic dyslipidemia of abdominal obesity . J Lipid Res . 2001;42:2007–2014
  56. Nieves DJ , Cnop M , Retzlaff B , et al.   The atherogenic lipoprotein profile associated with obesity and insulin resistance is largely attributable to intra-abdominal fat . Diabetes . 2003;52:172–179
  57. Pykalisto OJ , Smith PH , Brunzell JD . Determinants of human adipose tissue lipoprotein lipase. Effect of diabetes and obesity on basal- and diet-induced activity . J Clin Invest . 1975;56:1108–1117
  58. Juhan-Vague I , Morange PE , Alessi MC . The insulin resistance syndrome (implications for thrombosis and cardiovascular disease) . Pathophysiol Haemost Thromb . 2002;32:269–273
  59. Noushmehr H , D’Amico E , Farilla L , et al.   Fatty acid translocase (FAT/CD36) is localized on insulin-containing granules in human pancreatic beta-cells and mediates fatty acid effects on insulin secretion . Diabetes . 2005;54:472–481
  60. Dubois M , Kerr-Conte J , Gmyr V , et al.   Non-esterified fatty acids are deleterious for human pancreatic islet function at physiological glucose concentration . Diabetologia . 2004;47:463–469
  61. Brochu M , Starling RD , Tchernof A , et al.   Visceral adipose tissue is an independent correlate of glucose disposal in older obese postmenopausal women . J Clin Endocrinol Metab . 2000;85:2378–2384
  62. Nyholm B , Nielsen MF , Kristensen K , et al.   Evidence of increased visceral obesity and reduced physical fitness in healthy insulin-resistant first-degree relatives of type 2 diabetic patients . Eur J Endocrinol . 2004;150:207–214
  63. Carey DG , Jenkins AB , Campbell LV , et al.   Abdominal fat and insulin resistance in normal and overweight women (direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM) . Diabetes . 1996;45:633–638
  64. Cnop M , Landchild MJ , Vidal J , et al.   The concurrent accumulation of intra-abdominal and subcutaneous fat explains the association between insulin resistance and plasma leptin concentrations (distinct metabolic effects of two fat compartments) . Diabetes . 2002;51:1005–1015
  65. Cnop M , Hannaert JC , Grupping AY , et al.   Low density lipoprotein can cause death of islet beta-cells by its cellular uptake and oxidative modification . Endocrinology . 2002;143:3449–3453
  66. Wagenknecht LE , Langefeld CD , Scherzinger AL , et al.   Insulin sensitivity, insulin secretion, and abdominal fat (the Insulin Resistance Atherosclerosis Study (IRAS) Family Study) . Diabetes . 2003;52:2490–2496
  67. Fujimoto WY , Abbate SL , Kahn SE , et al.   The visceral adiposity syndrome in Japanese-American men . Obes Res . 1994;2:364–371
  68. Steppan CM , Bailey ST , Bhat S , et al.   The hormone resistin links obesity to diabetes . Nature . 2001;409:307–312
  69. Reilly MP , Lehrke M , Wolfe ML , et al.   Resistin is an inflammatory marker of atherosclerosis in humans . Circulation . 2005;111:932–939
  70. Hara T , Fujiwara H , Shoji T , et al.   Decreased plasma adiponectin levels in young obese males . J Atheroscler Thromb . 2003;10:234–238
  71. Kern PA , Di Gregorio GB , Lu T , et al.   Adiponectin expression from human adipose tissue (relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression) . Diabetes . 2003;52:1779–1785
  72. Berg AH , Combs TP , Du X , et al.   The adipocyte-secreted protein Acrp30 enhances hepatic insulin action . Nat Med . 2001;7:947–953
  73. Xydakis AM , Case CC , Jones PH , et al.   Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals (the impact of rapid weight loss through caloric restriction) . J Clin Endocrinol Metab . 2004;89:2697–2703
  74. Okamoto Y , Kihara S , Ouchi N , et al.   Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice . Circulation . 2002;106:2767–2770
  75. Hotta K , Funahashi T , Arita Y , et al.   Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients . Arterioscler Thromb Vasc Biol . 2000;20:1595–1599
  76. Juhan-Vague I , Alessi MC , Mavri A , et al.   Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk . J Thromb Haemost . 2003;1:1575–1579
  77. Shimomura I , Funahashi T , Takahashi M , et al.   Enhanced expression of PAI-1 in visceral fat (possible contributor to vascular disease in obesity) . Nat Med . 1996;2:800–803
  78. Uysal KT , Wiesbrock SM , Marino MW , et al.   Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function . Nature . 1997;389:610–614
  79. Ford ES , Ajani UA , Mokdad AH . The metabolic syndrome and concentrations of C-reactive protein among U.S. youth . Diabetes Care . 2005;28:878–881
  80. You T , Yang R , Lyles MF , et al.   Abdominal adipose tissue cytokine gene expression (relationship to obesity and metabolic risk factors) . Am J Physiol Endocrinol Metab . 2005;288:E741–E747
  81. Weisberg SP , McCann D , Desai M , et al.   Obesity is associated with macrophage accumulation in adipose tissue . J Clin Invest . 2003;112:1796–1808
  82. Montague CT , O’Rahilly S . The perils of portliness (causes and consequences of visceral adiposity) . Diabetes . 2000;49:883–888
  83. Spiegelman BM , Flier JS . Obesity and the regulation of energy balance . Cell . 2001;104:531–543
  84. Ruan H , Lodish HF . Insulin resistance in adipose tissue (direct and indirect effects of tumor necrosis factor-alpha) . Cytokine Growth Factor Rev . 2003;14:447–455
  85. Chen J , Wildman RP , Hamm LL , et al.   Association between inflammation and insulin resistance in U.S. nondiabetic adults (results from the Third National Health and Nutrition Examination Survey) . Diabetes Care . 2004;27:2960–2965
  86. Ferreira I , Henry RM , Twisk JW , et al.   The metabolic syndrome, cardiopulmonary fitness, and subcutaneous trunk fat as independent determinants of arterial stiffness (the Amsterdam Growth and Health Longitudinal Study) . Arch Intern Med . 2005;165:875–882
  87. Scuteri A , Najjar SS , Muller DC , et al.   Metabolic syndrome amplifies the age-associated increases in vascular thickness and stiffness . J Am Coll Cardiol . 2004;43:1388–1395
  88. Urbina EM , Srinivasan SR , Kieltyka RL , et al.   Correlates of carotid artery stiffness in young adults (The Bogalusa Heart Study) . Atherosclerosis . 2004;176:157–164
  89. Mikhail N , Tuck ML . Insulin and the vasculature . Curr Hypertens Rep . 2000;2:148–153
  90. Rakugi H , Kamide K , Ogihara T . Vascular signaling pathways in the metabolic syndrome . Curr Hypertens Rep . 2002;4:105–111
  91. Le Roith D , Zick Y . Recent advances in our understanding of insulin action and insulin resistance . Diabetes Care . 2001;24:588–597
  92. Cusi K , Maezono K , Osman A , et al.   Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle . J Clin Invest . 2000;105:311–320
  93. Dandona P , Aljada A , Mohanty P . The anti-inflammatory and potential anti-atherogenic effect of insulin (a new paradigm) . Diabetologia . 2002;45:924–930
  94. Montagnani M , Golovchenko I , Kim I , et al.   Inhibition of phosphatidylinositol 3-kinase enhances mitogenic actions of insulin in endothelial cells . J Biol Chem . 2002;277:1794–1799
  95. Hsueh WA , Law RE . Insulin signaling in the arterial wall . Am J Cardiol . 1999;84:21J–24J
  96. Barbato JE , Zuckerbraun BS , Overhaus M , et al.   Nitric oxide modulates vascular inflammation and intimal hyperplasia in insulin resistance and the metabolic syndrome . Am J Physiol Heart Circ Physiol . 2005;289:H228–H236
  97. Meigs JB , Hu FB , Rifai N , et al.   Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus . JAMA . 2004;291:1978–1986
  98. De Jongh RT , Serné EH , IJzerman RG , et al.   Impaired microvascular function in obesity (implications for obesity-associated microangiopathy, hypertension, and insulin resistance) . Circulation . 2004;109:2529–2535
  99. Engeli S , Gorzelniak K , Kreutz R , et al.   Co-expression of renin-angiotensin system genes in human adipose tissue . J Hypertens . 1999;17:555–560
  100. Ruano M , Silvestre V , Castro R , et al.   Morbid obesity, hypertensive disease and the renin-angiotensin-aldosterone axis . Obes Surg . 2005;15:670–676
  101. Rattarasarn C , Leelawattana R , Soonthornpun S , et al.   Regional abdominal fat distribution in lean and obese Thai type 2 diabetic women (relationships with insulin sensitivity and cardiovascular risk factors) . Metabolism . 2003;52:1444–1447
  102. Bacha F , Saad R , Gungor N , et al.   Obesity, regional fat distribution, and syndrome X in obese black versus white adolescents (race differential in diabetogenic and atherogenic risk factors) . J Clin Endocrinol Metab . 2003;88:2534–2540
  103. Tuck ML . Obesity, the sympathetic nervous system, and essential hypertension . Hypertension . 1992;19:I67–I77
  104. Ruderman N , Chisholm D , Pi-Sunyer X , et al.   The metabolically obese, normal-weight individual revisited . Diabetes . 1998;47:699–713
  105. Dvorak RV , DeNino WF , Ades PA , et al.   Phenotypic characteristics associated with insulin resistance in metabolically obese but normal-weight young women . Diabetes . 1999;48:2210–2214
  106. Chandalia M , Abate N , Garg A , et al.   Relationship between generalized and upper body obesity to insulin resistance in Asian Indian men . J Clin Endocrinol Metab . 1999;84:2329–2335
  107. Raji A , Seely EW , Arky RA , et al.   Body fat distribution and insulin resistance in healthy Asian Indians and Caucasians . J Clin Endocrinol Metab . 2001;86:5366–5371
  108. St-Pierre AC , Cantin B , Mauriege P , et al.   Insulin resistance syndrome, body mass index and the risk of ischemic heart disease . Canadian Medical Association Journal . 2005;172:1301–1305
  109. Brage S , Wedderkopp N , Ekelund U , et al.   Features of the metabolic syndrome are associated with objectively measured physical activity and fitness in Danish children (the European Youth Heart Study (EYHS)) . Diabetes Care . 2004;27:2141–2148
  110. Ferreira I , Twisk JW , van Mechelen W , et al.   Development of fatness, fitness, and lifestyle from adolescence to the age of 36 years: determinants of the metabolic syndrome in young adults: the amsterdam growth and health longitudinal study . Arch Intern Med . 2005;165:42–48
  111. Freire RD , Cardoso MA , Gimeno SG , et al.   Dietary fat is associated with metabolic syndrome in Japanese Brazilians . Diabetes Care . 2005;28:1779–1785
  112. Sonnenberg L , Pencina M , Kimokoti R , et al.   Dietary patterns and the metabolic syndrome in obese and non-obese Framingham women . Obes Res . 2005;13:153–162
  113. Freiberg MS , Cabral HJ , Heeren TC , et al.   Alcohol consumption and the prevalence of the Metabolic Syndrome in the US (a cross-sectional analysis of data from the Third National Health and Nutrition Examination Survey) . Diabetes Care . 2004;27:2954–2959
  114. McKeown NM , Meigs JB , Liu S , et al.   Carbohydrate nutrition, insulin resistance, and the prevalence of the metabolic syndrome in the Framingham Offspring Cohort . Diabetes Care . 2004;27:538–546
  115. Ong KK , Ahmed ML , Emmett PM , et al.   Association between postnatal catch-up growth and obesity in childhood (prospective cohort study) . British Medical Journal . 2000;320:967–971
  116. Jaquet D , Deghmoun S , Chevenne D , et al.   Dynamic change in adiposity from fetal to postnatal life is involved in the metabolic syndrome associated with reduced fetal growth . Diabetologia . 2005;48:849–855
  117. Biddinger SB , Almind K , Miyazaki M , et al.   Effects of diet and genetic background on sterol regulatory element-binding protein-1c, stearoyl-CoA desaturase 1, and the development of the metabolic syndrome . Diabetes . 2005;54:1314–1323
  118. Seidelmann SB , De Luca C , Leibel RL , et al.   Quantitative trait locus mapping of genetic modifiers of metabolic syndrome and atherosclerosis in low-density lipoprotein receptor-deficient mice (identification of a locus for metabolic syndrome and increased atherosclerosis on chromosome 4) . Arterioscler Thromb Vasc Biol . 2005;25:204–210
  119. Collier GR , McMillan JS , Windmill K , et al.   Beacon (a novel gene involved in the regulation of energy balance) . Diabetes . 2000;49:1766–1771
  120. Jowett JB , Elliott KS , Curran JE , et al.   Genetic variation in BEACON influences quantitative variation in metabolic syndrome-related phenotypes . Diabetes . 2004;53:2467–2472
  121. Guettier JM , Georgopoulos A , Tsai MY , et al.   Polymorphisms in the fatty acid-binding protein 2 and apolipoprotein C-III genes are associated with the metabolic syndrome and dyslipidemia in a South Indian population . J Clin Endocrinol Metab . 2005;90:1705–1711
  122. Tang W , Miller MB , Rich SS , et al.   Linkage analysis of a composite factor for the multiple metabolic syndrome (the National Heart, Lung, and Blood Institute Family Heart Study) . Diabetes . 2003;52:2840–2847
  123. Ng MC , So WY , Lam VK , et al.   Genome-wide scan for metabolic syndrome and related quantitative traits in Hong Kong Chinese and confirmation of a susceptibility locus on chromosome 1q21-q25 . Diabetes . 2004;53:2676–2683
  124. Rich SS , Bowden DW , Haffner SM , et al.   A genome scan for fasting insulin and fasting glucose identifies a quantitative trait locus on chromosome 17p (the insulin resistance atherosclerosis study (IRAS) family study) . Diabetes . 2005;54:290–295
  125. Hamid YH , Rose CS , Urhammer SA , et al.   Variations of the interleukin-6 promoter are associated with features of the metabolic syndrome in Caucasian Danes . Diabetologia . 2005;48:251–260
  126. Ohashi K , Ouchi N , Kihara S , et al.   Adiponectin I164T mutation is associated with the metabolic syndrome and coronary artery disease . J Am Coll Cardiol . 2004;43:1195–1200
  127. National Institutes of Health . Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults—The Evidence Report . Obes Res . 1998;6(suppl 2):51S–209S
  128. Lee IM , Manson JE , Hennekens CH , et al.   Body weight and mortality. A 27-year follow-up of middle-aged men . JAMA . 1993;270:2823–2828
  129. Manson JE , Colditz GA , Stampfer MJ , et al.   A prospective study of obesity and risk of coronary heart disease in women . N Engl J Med . 1990;322:882–889
  130. Wei M , Kampert JB , Barlow CE , et al.   Relationship between low cardiorespiratory fitness and mortality in normal-weight, overweight, and obese men . JAMA . 1999;282:1547–1553
  131. Jousilahti P , Tuomilehto J , Vartiainen E , et al.   Body weight, cardiovascular risk factors, and coronary mortality. 15-year follow-up of middle-aged men and women in eastern Finland . Circulation . 1996;93:1372–1379
  132. Yeh WT , Chang HY , Yeh CJ , et al.   Do centrally obese Chinese with normal BMI have increased risk of metabolic disorders? . Int J Obes (Lond) . 2005;29:818–825
  133. Jensen MD , Haymond MW , Rizza RA , et al.   Influence of body fat distribution on free fatty acid metabolism in obesity . J Clin Invest . 1989;83:1168–1173
  134. Perseghin G , Ghosh S , Gerow K , et al.   Metabolic defects in lean nondiabetic offspring of NIDDM parents (a cross-sectional study) . Diabetes . 1997;46:1001–1009
  135. Abate N , Chandalia M , Snell PG , et al.   Adipose tissue metabolites and insulin resistance in nondiabetic Asian Indian men . J Clin Endocrinol Metab . 2004;89:2750–2755
  136. Abate N , Garg A , Peshock RM , et al.   Relationships of generalized and regional adiposity to insulin sensitivity in men . J Clin Invest . 1995;96:88–98
  137. Abate N , Garg A , Peshock RM , et al.   Relationship of generalized and regional adiposity to insulin sensitivity in men with NIDDM . Diabetes . 1996;45:1684–1693
  138. Goodpaster BH , Thaete FL , Simoneau JA , et al.   Subcutaneous abdominal fat and thigh muscle composition predict insulin sensitivity independently of visceral fat . Diabetes . 1997;46:1579–1585
  139. Sites CK , Calles-Escandon J , Brochu M , et al.   Relation of regional fat distribution to insulin sensitivity in postmenopausal women . Fertil Steril . 2000;73:61–65
  140. Nielsen S , Guo Z , Johnson CM , et al.   Splanchnic lipolysis in human obesity . J Clin Invest . 2004;113:1582–1588
  141. Bosello O , Zamboni M . Visceral obesity and metabolic syndrome . Obes Rev . 2000;1:47–56
  142. Rendell M , Hulthen UL , Tornquist C , et al.   Relationship between abdominal fat compartments and glucose and lipid metabolism in early postmenopausal women . J Clin Endocrinol Metab . 2001;86:744–749
  143. Ross R , Freeman J , Hudson R , et al.   Abdominal obesity, muscle composition, and insulin resistance in premenopausal women . J Clin Endocrinol Metab . 2002;87:5044–5051
  144. Pouliot MC , Despres JP , Lemieux S , et al.   Waist circumference and abdominal sagittal diameter (best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women) . Am J Cardiol . 1994;73:460–468
  145. Zhu S , Heymsfield SB , Toyoshima H , et al.   Race-ethnicity-specific waist circumference cutoffs for identifying cardiovascular disease risk factors . Am J Clin Nutr . 2005;81:409–415
  146. Janssen I . Waist circumference and not body-mass index explains obesity-related health risk . Am J Clin Nutr . 2004;79:379–384
  147. Hayashi T , Boyko EJ , Leonetti DL , et al.   Visceral adiposity and the risk of impaired glucose tolerance (a prospective study among Japanese Americans) . Diabetes Care . 2003;26:650–655
  148. Hayashi T , Boyko EJ , Leonetti DL , et al.   Visceral adiposity is an independent predictor of incident hypertension in Japanese Americans . Ann Intern Med . 2004;140:992–1000
  149. Wahrenberg H , Hertel K , Leijonhufvud BM , et al.   Use of waist circumference to predict insulin resistance (retrospective study) . BMJ . 2005;330:1363–1364
  150. Mori Y , Hoshino K , Yokota K , et al.   Increased visceral fat and impaired glucose tolerance predict the increased risk of metabolic syndrome in Japanese middle-aged men . Exp Clin Endocrinol Diabetes . 2005;113:334–339
  151. Kanai H , Tokunaga K , Fujioka S , et al.   Decrease in intra-abdominal visceral fat may reduce blood pressure in obese hypertensive women . Hypertension . 1996;27:125–129
  152. Ribeiro-Filho FF , Faria AN , Kohlmann NE , et al.   Two-hour insulin determination improves the ability of abdominal fat measurement to identify risk for the metabolic syndrome . Diabetes Care . 2003;26:1725–1730
  153. Nicklas BJ , Penninx BW , Ryan AS , et al.   Visceral adipose tissue cutoffs associated with metabolic risk factors for coronary heart disease in women . Diabetes Care . 2003;26:1413–1420
  154. Phillips GB , Jing T , Heymsfield SB . Relationships in men of sex hormones, insulin, adiposity, and risk factors for myocardial infarction . Metabolism . 2003;52:784–790
  155. Panagiotakos DB , Pitsavos C , Chrysohoou C , et al.   Impact of lifestyle habits on the prevalence of the metabolic syndrome among Greek adults from the ATTICA study . Am Heart J . 2004;147:106–112
  156. Benetos A , Thomas F , Bean K , et al.   Prognostic value of systolic and diastolic blood pressure in treated hypertensive men . Arch Intern Med . 2002;162:577–581
  157. Yusuf S . Two decades of progress in preventing vascular disease . Lancet . 2002;360:2–3
  158. Chobanian AV , Bakris GL , Black HR , et al.   The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (the JNC 7 report) . JAMA . 2003;289:2560–2572
  159. Chiasson JL , Josse RG , Gomis R , et al.   Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance (the STOP-NIDDM trial) . JAMA . 2003;290:486–494
  160. Gordon T , Castelli WP , Hjortland MC , et al.   High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study . Am J Med . 1977;62:707–714
  161. Sacks FM , Tonkin AM , Shepherd J , et al.   Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors (the Prospective Pravastatin Pooling Project) . Circulation . 2000;102:1893–1900
  162. Hokanson JE , Austin MA . Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level (a meta-analysis of population-based prospective studies) . J Cardiovasc Risk . 1996;3:213–219
  163. Jeppesen J , Hein HO , Suadicani P , et al.   Relation of high TG-low HDL cholesterol and LDL cholesterol to the incidence of ischemic heart disease. An 8-year follow-up in the Copenhagen Male Study . Arterioscler Thromb Vasc Biol . 1997;17:1114–1120
  164. Han T , Woo SK , Shin S , et al.   Visceral adiposity and apolipoprotein C-III in apolipoprotein B-containing lipoproteins are independent predictors in determining atherogenic lipid profiles . Ann Nutr Metab . 2006;50:31–36
  165. Solati M , Ghanbarian A , Rahmani M , et al.   Cardiovascular risk factors in males with hypertriglycemic waist (Tehran Lipid and Glucose Study) . Int J Obes Relat Metab Disord . 2004;28:706–709
  166. Blackburn P , Lamarche B , Couillard C , et al.   Postprandial hyperlipidemia (another correlate of the “hypertriglyceridemic waist” phenotype in men) . Atherosclerosis . 2003;171:327–336
  167. Bos G , Dekker JM , Heine RJ . Non-HDL cholesterol contributes to the “hypertriglyceridemic waist” as a cardiovascular risk factor (the Hoorn study) . Diabetes Care . 2004;27:283–284
  168. St-Pierre J , Lemieux I , Vohl MC , et al.   Contribution of abdominal obesity and hypertriglyceridemia to impaired fasting glucose and coronary artery disease . Am J Cardiol . 2002;90:15–18
  169. Dokras A , Bochner M , Hollinrake E , et al.   Screening women with polycystic ovary syndrome for metabolic syndrome . Obstet Gynecol . 2005;106:131–137
  170. Wang Y , Oram JF . Unsaturated fatty acids inhibit cholesterol efflux from macrophages by increasing degradation of ATP-binding cassette transporter A1 . J Biol Chem . 2002;277:5692–5697
  171. Hansel B , Giral P , Nobecourt E , et al.   Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity . J Clin Endocrinol Metab . 2004;89:4963–4971
  172. Holvoet P , Kritchevsky SB , Tracy RP , et al.   The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well-functioning elderly people in the health, aging, and body composition cohort . Diabetes . 2004;53:1068–1073
  173. Sattar N , Williams K , Sniderman AD , et al.   Comparison of the associations of apolipoprotein B and non-high-density lipoprotein cholesterol with other cardiovascular risk factors in patients with the metabolic syndrome in the Insulin Resistance Atherosclerosis Study . Circulation . 2004;110:2687–2693
  174. Wallenfeldt K , Bokemark L , Wikstrand J , et al.   Apolipoprotein B/apolipoprotein A-I in relation to the metabolic syndrome and change in carotid artery intima-media thickness during 3 years in middle-aged men . Stroke . 2004;35:2248–2252
  175. Satoh A , Adachi H , Tsuruta M , et al.   High plasma level of remnant-like particle cholesterol in the metabolic syndrome . Diabetes Care . 2005;28:2514–2518
  176. Ridker PM , Hennekens CH , Buring JE , et al.   C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women . N Engl J Med . 2000;342:836–843
  177. Ridker PM , Rifai N , Rose L , et al.   Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events . N Engl J Med . 2002;347:1557–1565
  178. Rutter MK , Meigs JB , Sullivan LM , et al.   C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study . Circulation . 2004;110:380–385
  179. Piche ME , Lemieux S , Weisnagel SJ , et al.   Relation of high-sensitivity C-reactive protein, interleukin-6, tumor necrosis factor-alpha, and fibrinogen to abdominal adipose tissue, blood pressure, and cholesterol and triglyceride levels in healthy postmenopausal women . Am J Cardiol . 2005;96:92–97
  180. Mardi T , Toker S , Melamed S , et al.   Increased erythropoiesis and subclinical inflammation as part of the metabolic syndrome . Diabetes Res Clin Pract . 2005;69:249–255
  181. Santos AC , Lopes C , Guimaraes JT , Barros H . Central obesity as a major determinant of increased high-sensitivity C-reactive protein in metabolic syndrome . Int J Obes (Lond) . 2005;29:1452–1456
  182. Kumar BN , Meyer HE , Wandel M , et al.   Ethnic differences in obesity among immigrants from developing countries, in Oslo, Norway . Int J Obes Relat Metab Disord . 2006;30:684–690
  183. Muntner P , He J , Chen J , et al.   Prevalence of non-traditional cardiovascular disease risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome (analysis of the Third National Health and Nutrition Examination Survey (NHANES III)) . Ann Epidemiol . 2004;14:686–695
  184. Langer RD , Pradhan AD , Lewis CE , et al.   Baseline associations between postmenopausal hormone therapy and inflammatory, haemostatic, and lipid biomarkers of coronary heart disease. The Women’s Health Initiative Observational Study . Thromb Haemost . 2005;93:1108–1116
  185. Verma S , Kuliszewski MA , Li SH , et al.   C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function (further evidence of a mechanistic link between C-reactive protein and cardiovascular disease) . Circulation . 2004;109:2058–2067
  186. Ridker PM . High-sensitivity C-reactive protein (potential adjunct for global risk assessment in the primary prevention of cardiovascular disease) . Circulation . 2001;103:1813–1818
  187. Ridker PM . Clinical application of C-reactive protein for cardiovascular disease detection and prevention . Circulation . 2003;107:363–369
  188. Malik S , Wong ND , Franklin S , et al.   Cardiovascular disease in U.S. patients with metabolic syndrome, diabetes, and elevated C-reactive protein . Diabetes Care . 2005;28:690–693
  189. Pearson TA , Mensah GA , Alexander RW , et al.   Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association . Circulation . 2003;107:499–511
  190. Anand SS , Yi Q , Gerstein H , et al.   Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease . Circulation . 2003;108:420–425
  191. Pischon T , Girman CJ , Hotamisligil GS , et al.   Plasma adiponectin levels and risk of myocardial infarction in men . JAMA . 2004;291:1730–1737
  192. Tzou WS , Douglas PS , Srinivasan SR , et al.   Increased subclinical atherosclerosis in young adults with metabolic syndrome (the Bogalusa Heart Study) . J Am Coll Cardiol . 2005;46:457–463
  193. McNeill AM , Rosamond WD , Girman CJ , et al.   Prevalence of coronary heart disease and carotid arterial thickening in patients with the metabolic syndrome (The ARIC Study) . Am J Cardiol . 2004;94:1249–1254
  194. Ellison RC , Zhang Y , Wagenknecht LE , et al.   Relation of the metabolic syndrome to calcified atherosclerotic plaque in the coronary arteries and aorta . Am J Cardiol . 2005;95:1180–1186
  195. Wong ND , Sciammarella MG , Polk D , et al.   The metabolic syndrome, diabetes, and subclinical atherosclerosis assessed by coronary calcium . J Am Coll Cardiol . 2003;41:1547–1553
  196. Kullo IJ , Cassidy AE , Peyser PA , et al.   Association between metabolic syndrome and subclinical coronary atherosclerosis in asymptomatic adults . Am J Cardiol . 2004;94:1554–1558
  197. Wong ND , Rozanski A , Gransar H , et al.   Metabolic syndrome and diabetes are associated with an increased likelihood of inducible myocardial ischemia among patients with subclinical atherosclerosis . Diabetes Care . 2005;28:1445–1450
  198. Chinali M , Devereux RB , Howard BV , et al.   Comparison of cardiac structure and function in American Indians with and without the metabolic syndrome (the Strong Heart Study) . Am J Cardiol . 2004;93:40–44
  199. Ford ES . Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome (a summary of the evidence) . Diabetes Care . 2005;28:1769–1778
  200. Sattar N , Gaw A , Scherbakova O , et al.   Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study . Circulation . 2003;108:414–419
  201. McNeill AM , Rosamond WD , Girman CJ , et al.   The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study . Diabetes Care . 2005;28:385–390
  202. Hunt KJ , Resendez RG , Williams K , et al.   National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study . Circulation . 2004;110:1251–1257
  203. Ninomiya JK , L’Italien G , Criqui MH , et al.   Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey . Circulation . 2004;109:42–46
  204. Schillaci G , Pirro M , Vaudo G , et al.   Prognostic value of the metabolic syndrome in essential hypertension . J Am Coll Cardiol . 2004;43:1817–1822
  205. Malik S , Wong ND , Franklin SS , et al.   Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults . Circulation . 2004;110:1245–1250
  206. Stern MP , Williams K , Hunt KJ . Impact of diabetes/metabolic syndrome in patients with established cardiovascular disease . Atheroscler Suppl . 2005;6:3–6
  207. Zeller M , Steg PG , Ravisy J , et al.   Prevalence and impact of metabolic syndrome on hospital outcomes in acute myocardial infarction . Arch Intern Med . 2005;165:1192–1198
  208. Kataoka Y , Yasuda S , Morii I , et al.   Quantitative coronary angiographic studies of patients with angina pectoris and impaired glucose tolerance . Diabetes Care . 2005;28:2217–2222
  209. D’Agostino RB , Grundy S , Sullivan LM , et al.   Validation of the Framingham coronary heart disease prediction scores (results of a multiple ethnic groups investigation) . JAMA . 2001;286:180–187
  210. Stern MP , Williams K , Gonzalez-Villalpando C , et al.   Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? . Diabetes Care . 2004;27:2676–2681
  211. Girman CJ , Rhodes T , Mercuri M , et al.   The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) . Am J Cardiol . 2004;93:136–141
  212. Kelley DE , Thaete FL , Troost F , et al.   Subdivisions of subcutaneous abdominal adipose tissue and insulin resistance . Am J Physiol Endocrinol Metab . 2000;278:E941–E948
  213. Ferrannini E , Natali A , Capaldo B , et al.  European Group for the Study of Insulin Resistance (EGIR)   Insulin resistance, hyperinsulinemia, and blood pressure (role of age and obesity) . Hypertension . 1997;30:1144–1149
  214. DeFronzo RA , Goldberg M , Agus ZS . The effects of glucose and insulin on renal electrolyte transport . J Clin Invest . 1976;58:83–90
  215. Angelico F , Del Ben M , Conti R , et al.   Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease . J Clin Endocrinol Metab . 2005;90:1578–1582
  216. The Diabetes Prevention Program Research Group . Lipid, lipoproteins, C-reactive protein, and hemostatic factors at baseline in the diabetes prevention program . Diabetes Care . 2005;28:2472–2479
  217. Reilly MP , Wolfe ML , Rhodes T , et al.   Measures of insulin resistance add incremental value to the clinical diagnosis of metabolic syndrome in association with coronary atherosclerosis . Circulation . 2004;110:803–809
  218. Bonora E , Kiechl S , Willeit J , et al.   Population-based incidence rates and risk factors for type 2 diabetes in white individuals (the Bruneck study) . Diabetes . 2004;53:1782–1789
  219. Eschwege E , Balkau B . Hyperglycaemia (link to excess mortality) . Int J Clin Pract Suppl . 2001;3–6
  220. Jensen CC , Cnop M , Hull RL , et al.   Beta-cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the U.S . Diabetes . 2002;51:2170–2178
  221. Knowler WC , Barrett-Connor E , Fowler SE , et al.   Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin . N Engl J Med . 2002;346:393–403
  222. Edelstein SL , Knowler WC , Bain RP , et al.   Predictors of progression from impaired glucose tolerance to NIDDM (an analysis of six prospective studies) . Diabetes . 1997;46:701–710
  223. Lillioja S , Mott DM , Howard BV , et al.   Impaired glucose tolerance as a disorder of insulin action. Longitudinal and cross-sectional studies in Pima Indians . N Engl J Med . 1988;318:1217–1225
  224. Saad MF , Knowler WC , Pettitt DJ , et al.   The natural history of impaired glucose tolerance in the Pima Indians . N Engl J Med . 1988;319:1500–1506
  225. Modan M , Karasik A , Halkin H , et al.   Effect of past and concurrent body mass index on prevalence of glucose intolerance and type 2 (non-insulin-dependent) diabetes and on insulin response. The Israel study of glucose intolerance, obesity and hypertension . Diabetologia . 1986;29:82–89
  226. Gabir MM , Hanson RL , Dabelea D , et al.   The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes . Diabetes Care . 2000;23:1108–1112
  227. Charles MA , Fontbonne A , Thibult N , et al.  Paris prospective study   Risk factors for NIDDM in white population . Diabetes . 1991;40:796–799
  228. de Vegt F , Dekker JM , Jager A , et al.   Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population (the Hoorn Study) . JAMA . 2001;285:2109–2113
  229. Vaccaro O , Ruffa G , Imperatore G , et al.   Risk of diabetes in the new diagnostic category of impaired fasting glucose (a prospective analysis) . Diabetes Care . 1999;22:1490–1493
  230. Stern MP , Williams K , Haffner SM . Identification of persons at high risk for type 2 diabetes mellitus (do we need the oral glucose tolerance test?) . Ann Intern Med . 2002;136:575–581
  231. Lorenzo C , Okoloise M , Williams K , et al.   The metabolic syndrome as predictor of type 2 diabetes (the San Antonio heart study) . Diabetes Care . 2003;26:3153–3159
  232. Weiss R , Taksali SE , Tamborlane WV , et al.   Predictors of changes in glucose tolerance status in obese youth . Diabetes Care . 2005;28:902–909
  233. Pan XR , Li GW , Hu YH , et al.  The Da Qing IGT and Diabetes Study   Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance . Diabetes Care . 1997;20:537–544
  234. Tuomilehto J , Lindstrom J , Eriksson JG , et al.   Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance . N Engl J Med . 2001;344:1343–1350
  235. Buchanan TA , Xiang AH , Peters RK , et al.   Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women . Diabetes . 2002;51:2796–2803
  236. Nelson KM , Boyko EJ . Predicting impaired glucose tolerance using common clinical information (data from the Third National Health and Nutrition Examination Survey) . Diabetes Care . 2003;26:2058–2062
  237. Meigs JB , Williams K , Sullivan LM , et al.   Using metabolic syndrome traits for efficient detection of impaired glucose tolerance . Diabetes Care . 2004;27:1417–1426
  238. The DECODE Study Group . Consequences of the new diagnostic criteria for diabetes in older men and women. DECODE Study (Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe) . Diabetes Care . 1999;22:1667–1671
  239. Shaw JE , de Courten M , Boyko EJ , et al.   Impact of new diagnostic criteria for diabetes on different populations . Diabetes Care . 1999;22:762–766
  240. Saydah SH , Byrd-Holt D , Harris MI . Projected impact of implementing the results of the diabetes prevention program in the U.S. population . Diabetes Care . 2002;25:1940–1945
  241. Anand SS , Razak F , Vuksan V , et al.   Diagnostic strategies to detect glucose intolerance in a multiethnic population . Diabetes Care . 2003;26:290–296
  242. Lindahl B , Weinehall L , Asplund K , et al.   Screening for impaired glucose tolerance. Results from a population-based study in 21,057 individuals . Diabetes Care . 1999;22:1988–1992
  243. American Diabetes Association . Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus . Diabetes Care . 1997;20:1183–1197
  244. Hanley AJ , Festa A , D’Agostino RB , et al.   Metabolic and inflammation variable clusters and prediction of type 2 diabetes (factor analysis using directly measured insulin sensitivity) . Diabetes . 2004;53:1773–1781
  245. Grundy SM , Brewer HB , Cleeman JI , et al.   Definition of metabolic syndrome (Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition) . Circulation . 2004;109:433–438
  246. Hanson RL , Imperatore G , Bennett PH , et al.   Components of the “metabolic syndrome” and incidence of type 2 diabetes . Diabetes . 2002;51:3120–3127
  247. Laaksonen DE , Lakka HM , Niskanen LK , et al.   Metabolic syndrome and development of diabetes mellitus (application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study) . Am J Epidemiol . 2002;156:1070–1077
  248. Herman WH , Smith PJ , Thompson TJ , et al.   A new and simple questionnaire to identify people at increased risk for undiagnosed diabetes . Diabetes Care . 1995;18:382–387
  249. Baan CA , Ruige JB , Stolk RP , et al.   Performance of a predictive model to identify undiagnosed diabetes in a health care setting . Diabetes Care . 1999;22:213–219
  250. Schmidt MI , Duncan BB , Vigo A , et al.   Detection of undiagnosed diabetes and other hyperglycemia states (the Atherosclerosis Risk in Communities Study) . Diabetes Care . 2003;26:1338–1343
  251. Schmidt MI , Duncan BB , Bang H , et al.   Identifying individuals at high risk for diabetes (the Atherosclerosis Risk in Communities study) . Diabetes Care . 2005;28:2013–2018
  252. Tabaei BP , Herman WH . A multivariate logistic regression equation to screen for diabetes (development and validation) . Diabetes Care . 2002;25:1999–2003
  253. Barriga KJ , Hamman RF , Hoag S , et al.   Population screening for glucose intolerant subjects using decision tree analyses . Diabetes Res Clin Pract . 1996;34(suppl):S17–S29
  254. Griffin SJ , Little PS , Hales CN , et al.   Diabetes risk score (towards earlier detection of type 2 diabetes in general practice) . Diabetes Metab Res Rev . 2000;16:164–171
  255. Lindstrom J , Tuomilehto J . The diabetes risk score (a practical tool to predict type 2 diabetes risk) . Diabetes Care . 2003;26:725–731
  256. D’Agostino RB , Hamman RF , Karter AJ , et al.   Cardiovascular disease risk factors predict the development of type 2 diabetes (the insulin resistance atherosclerosis study) . Diabetes Care . 2004;27:2234–2240
  257. Kanaya AM , Fyr CL , de Rekeneire N , et al.   Predicting the development of diabetes in older adults (the derivation and validation of a prediction rule) . Diabetes Care . 2005;28:404–408
  258. Wen CP , Cheng TY , Tsai SP , et al.   Increased mortality risks of pre-diabetes (impaired fasting glucose) in Taiwan . Diabetes Care . 2005;28:2756–2761
  259. Laaksonen DE , Niskanen L , Nyyssonen K , et al.   C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men . Diabetologia . 2004;47:1403–1410
  260. Doi Y , Kiyohara Y , Kubo M , et al.   Elevated C-reactive protein is a predictor of the development of diabetes in a general Japanese population (the Hisayama Study) . Diabetes Care . 2005;28:2497–2500
  261. Sattar N , Scherbakova O , Ford I , et al.   Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study . Diabetes . 2004;53:2855–2860
  262. Rossi R , Cioni E , Nuzzo A , et al.   Endothelial-dependent vasodilation and incidence of type 2 diabetes in a population of healthy postmenopausal women . Diabetes Care . 2005;28:702–707
  263. Weyer C , Funahashi T , Tanaka S , et al.   Hypoadiponectinemia in obesity and type 2 diabetes (close association with insulin resistance and hyperinsulinemia) . J Clin Endocrinol Metab . 2001;86:1930–1935
  264. Lindsay RS , Funahashi T , Hanson RL , et al.   Adiponectin and development of type 2 diabetes in the Pima Indian population . Lancet . 2002;360:57–58
  265. Daimon M , Oizumi T , Saitoh T , et al.   Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese Population (the Funagata study) . Diabetes Care . 2003;26:2015–2020
  266. Spranger J , Kroke A , Mohlig M , et al.   Adiponectin and protection against type 2 diabetes mellitus . Lancet . 2003;361:226–228
  267. Duncan BB , Schmidt MI , Pankow JS , et al.   Adiponectin and the development of type 2 diabetes (the atherosclerosis risk in communities study) . Diabetes . 2004;53:2473–2478
  268. Osei K , Rhinesmith S , Gaillard T , et al.   Is glycosylated hemoglobin A1c a surrogate for metabolic syndrome in nondiabetic, first-degree relatives of African-American patients with type 2 diabetes? . J Clin Endocrinol Metab . 2003;88:4596–4601
  269. Thamer C , Tschritter O , Haap M , et al.   Elevated serum GGT concentrations predict reduced insulin sensitivity and increased intrahepatic lipids . Horm Metab Res . 2005;37:246–251
  270. Nannipieri M , Gonzales C , Baldi S , et al.   Liver enzymes, the metabolic syndrome, and incident diabetes (the Mexico City diabetes study) . Diabetes Care . 2005;28:1757–1762
  271. Yeh HC , Punjabi NM , Wang NY , et al.   Vital capacity as a predictor of incident type 2 diabetes (the Atherosclerosis Risk in Communities study) . Diabetes Care . 2005;28:1472–1479
  272. Ford ES , Mannino DM . Prospective association between lung function and the incidence of diabetes (findings from the National Health and Nutrition Examination Survey Epidemiologic Follow-up Study) . Diabetes Care . 2004;27:2966–2970
  273. Foy CG , Bell RA , Farmer DF , et al.   Smoking and incidence of diabetes among U.S. adults (findings from the Insulin Resistance Atherosclerosis Study) . Diabetes Care . 2005;28:2501–2507
  274. Cho NH , Lim S , Jang HC , et al.   Elevated homocysteine as a risk factor for the development of diabetes in women with a previous history of gestational diabetes mellitus (a 4-year prospective study) . Diabetes Care . 2005;28:2750–2755
  275. Schulze MB , Hoffmann K , Manson JE , et al.   Dietary pattern, inflammation, and incidence of type 2 diabetes in women . Am J Clin Nutr . 2005;82:675–684 quiz 714-5
  276. Ruhl CE , Everhart JE . Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States . Gastroenterology . 2003;124:71–79
  277. Nomura H , Kashiwagi S , Hayashi J , et al.   Prevalence of fatty liver in a general population of Okinawa, Japan . Jpn J Med . 1988;27:142–149
  278. Green RMNAS . H–hepatic metabolism and not simply the metabolic syndrome . Hepatology . 2003;38:14–17
  279. Donati G , Stagni B , Piscaglia F , et al.   Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes (role of insulin resistance) . Gut . 2004;53:1020–1023
  280. Marchesini G , Brizi M , Morselli-Labate AM , et al.   Association of nonalcoholic fatty liver disease with insulin resistance . Am J Med . 1999;107:450–455
  281. Wannamethee SG , Shaper AG , Lennon L , et al.   Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men . Diabetes Care . 2005;28:2913–2918
  282. Tiikkainen M , Bergholm R , Vehkavaara S , et al.   Effects of identical weight loss on body composition and features of insulin resistance in obese women with high and low liver fat content . Diabetes . 2003;52:701–707
  283. Liangpunsakul S , Chalasani N . Unexplained elevations in alanine aminotransferase in individuals with the metabolic syndrome (results from the third National Health and Nutrition Survey (NHANES III)) . Am J Med Sci . 2005;329:111–116
  284. Ruhl CE , Everhart JE . Relation of elevated serum alanine aminotransferase activity with iron and antioxidant levels in the United States . Gastroenterology . 2003;124:1821–1829
  285. Ioannou GN , Weiss NS , Boyko EJ , et al.   Contribution of metabolic factors to alanine aminotransferase activity in persons with other causes of liver disease . Gastroenterology . 2005;128:627–635
  286. Shen YH , Yang WS , Lee TH , et al.   Bright liver and alanine aminotransferase are associated with metabolic syndrome in adults . Obes Res . 2005;13:1238–1245
  287. Vehmas T , Kaukiainen A , Immonen-Raiha P , et al.   Liver echogenicity (relation to systemic blood pressure and other components of the metabolic syndrome) . Ultrasound Med Biol . 2005;31:293–299
  288. Bugianesi E , Pagotto U , Manini R , et al.   Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity . J Clin Endocrinol Metab . 2005;90:3498–3504
  289. Holt HB , Wild SH , Wood PJ , et al.   Non-esterified fatty acid concentrations are independently associated with hepatic steatosis in obese subjects . Diabetologia . 2006;49:141–148
  290. Apridonidze T , Essah PA , Iuorno MJ , et al.   Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome . J Clin Endocrinol Metab . 2005;90:1929–1935
  291. Ehrmann DA , Liljenquist DR , Kasza K , et al.   Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome . J Clin Endocrinol Metab . 2006;91:48–53
  292. Coviello AD , Legro RS , Dubaif A . Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance . J Clin Endocrinol Metab . 2006;91:492–497
  293. Puder JJ , Varga S , Kraenzlin M , et al.   Central fat excess in polycystic ovary syndrome (relation to low-grade inflammation and insulin resistance) . J Clin Endocrinol Metab . 2005;90:6014–6021
  294. Meyer C , McGrath BP , Teede HJ . Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease . J Clin Endocrinol Metab . 2005;90:5711–5716
  295. Paradisi G , Steinberg HO , Hempfling A , et al.   Polycystic ovary syndrome is associated with endothelial dysfunction . Circulation . 2001;103:1410–1415
  296. Orio F , Palomba S , Cascella T , et al.   Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome . J Clin Endocrinol Metab . 2004;89:4588–4593
  297. Guzick DS , Talbott EO , Sutton-Tyrrell K , et al.   Carotid atherosclerosis in women with polycystic ovary syndrome (initial results from a case-control study) . Am J Obstet Gynecol . 1996;174:1224–1229 discussion 1229-32.
  298. Talbott EO , Guzick DS , Sutton-Tyrrell K , et al.   Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women . Arterioscler Thromb Vasc Biol . 2000;20:2414–2421
  299. Wong TY , Duncan BB , Golden SH , et al.   Associations between the metabolic syndrome and retinal microvascular signs (the Atherosclerosis Risk In Communities study) . Invest Ophthalmol Vis Sci . 2004;45:2949–2954
  300. Lauenborg J , Mathiesen E , Hansen T , et al.   The prevalence of the metabolic syndrome in a Danish population of women with previous gestational diabetes mellitus is three-fold higher than in the general population . J Clin Endocrinol Metab . 2005;90:4004–4010
  301. Coughlin SR , Mawdsley L , Mugarza JA , et al.   Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome . Eur Heart J . 2004;25:735–741
  302. Teramoto S , Kume H , Matsuse T . Ambulatory blood pressure after sleep apnoea treatment . Lancet . 2002;360:341; author reply 341-2.
  303. Teramoto S , Kume H , Matsuse T , et al.   The risk of future cardiovascular diseases in the patients with OSAS is dependently or independently associated with obstructive sleep apnoea . Eur Respir J . 2001;17:573–574
  304. Grundy SM . Cholesterol gallstones (a fellow traveler with metabolic syndrome?) . Am J Clin Nutr . 2004;80:1–2
  305. Petrlova B , Rosolova H , Hess Z , et al.   Depressive disorders and the metabolic syndrome of insulin resistance . Semin Vasc Med . 2004;4:161–165
  306. Mackin P , Watkinson HM , Young AH . Prevalence of obesity, glucose homeostasis disorders and metabolic syndrome in psychiatric patients taking typical or atypical antipsychotic drugs (a cross-sectional study) . Diabetologia . 2005;48:215–221
  307. Jerico C , Knobel H , Montero M , et al.   Metabolic syndrome among HIV-infected patients (prevalence, characteristics, and related factors) . Diabetes Care . 2005;28:132–137
  308. Liu S , Song Y , Ford ES , et al.   Dietary calcium, vitamin D, and the prevalence of metabolic syndrome in middle-aged and older U.S. women . Diabetes Care . 2005;28:2926–2932
  309. Chiu KC , Chu A , Go VL , et al.   Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction . Am J Clin Nutr . 2004;79:820–825
  310. Ford ES , Ajani UA , McGuire LC , et al.   Concentrations of serum vitamin D and the metabolic syndrome among U.S. adults . Diabetes Care . 2005;28:1228–1230
  311. Eriksson KF , Lindgarde F . Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmo feasibility study . Diabetologia . 1991;34:891–898
  312. Li G , Hu Y , Yang W , et al.   Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus (the DA Qing IGT and Diabetes Study) . Diabetes Res Clin Pract . 2002;58:193–200
  313. Lindstrom J , Eriksson JG , Valle TT , et al.   Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish diabetes prevention study (results from a randomized clinical trial) . J Am Soc Nephrol . 2003;14:S108–S113
  314. Ratner R , Goldberg R , Haffner S , et al.   Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program . Diabetes Care . 2005;28:888–894
  315. Katzmarzyk PT , Church TS , Blair SN . Cardiorespiratory fitness attenuates the effects of the metabolic syndrome on all-cause and cardiovascular disease mortality in men . Arch Intern Med . 2004;164:1092–1097
  316. Lee S , Kuk JL , Katzmarzyk PT , et al.   Cardiorespiratory fitness attenuates metabolic risk independent of abdominal subcutaneous and visceral fat in men . Diabetes Care . 2005;28:895–901
  317. Desai MY , Nasir K , Rumberger JA , et al.   Relation of degree of physical activity to coronary artery calcium score in asymptomatic individuals with multiple metabolic risk factors . Am J Cardiol . 2004;94:729–732
  318. Petrella RJ , Lattanzio CN , Demeray A , et al.   Can adoption of regular exercise later in life prevent metabolic risk for cardiovascular disease? . Diabetes Care . 2005;28:694–701
  319. Krauss RM , Eckel RH , Howard B , et al.   AHA Dietary Guidelines: revision 2000: a statement for healthcare professionals from the Nutrition Committee of the American Heart Association . Circulation . 2000;102:2284–2299
  320. Franz MJ , Bantle JP , Beebe CA , et al.   Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications . Diabetes Care . 2003;26(suppl 1):S51–S61
  321. Seshadri P , Iqbal N , Stern L , et al.   A randomized study comparing the effects of a low-carbohydrate diet and a conventional diet on lipoprotein subfractions and C-reactive protein levels in patients with severe obesity . Am J Med . 2004;117:398–405
  322. Cutler JA , Follmann D , Allender PS . Randomized trials of sodium reduction (an overview) . Am J Clin Nutr . 1997;65:643S–651S
  323. Graudal NA , Galloe AM , Garred P . Effects of sodium restriction on blood pressure, renin, aldosterone, catecholamines, cholesterols, and triglyceride (a meta-analysis) . JAMA . 1998;279:1383–1391
  324. Pitsavos C , Panagiotakos DB , Chrysohoou C , et al.   The associations between physical activity, inflammation, and coagulation markers, in people with metabolic syndrome (the ATTICA study) . Eur J Cardiovasc Prev Rehabil . 2005;12:151–158
  325. Kelly AS , Wetzsteon RJ , Kaiser DR , et al.   Inflammation, insulin, and endothelial function in overweight children and adolescents (the role of exercise) . J Pediatr . 2004;145:731–736
  326. Aronson D , Sella R , Sheikh-Ahmad M , et al.   The association between cardiorespiratory fitness and C-reactive protein in subjects with the metabolic syndrome . J Am Coll Cardiol . 2004;44:2003–2007
  327. Esposito K , Marfella R , Ciotola M , et al.   Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome (a randomized trial) . JAMA . 2004;292:1440–1446
  328. Heilbronn LK , Noakes M , Clifton PM . Energy restriction and weight loss on very-low-fat diets reduce C-reactive protein concentrations in obese, healthy women . Arterioscler Thromb Vasc Biol . 2001;21:968–970
  329. Bastard JP , Jardel C , Bruckert E , et al.   Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss . J Clin Endocrinol Metab . 2000;85:3338–3342
  330. Orio F , Palomba S , Cascella T , et al.   Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome (results of a 6-month study) . J Clin Endocrinol Metab . 2005;90:6072–6076
  331. Wolford JK , Yeatts KA , Dhanjal SK , et al.   Sequence variation in PPARG may underlie differential response to troglitazone . Diabetes . 2005;54:3319–3325
  332. Xiang AH , Peters RK , Kjos SL , et al.   Effect of Pioglitazone on pancreatic β-cell function and diabetes risk in Hispanic women with prior gestational diabetes . Diabetes . 2006;55:517–522
  333. Torgerson JS , Hauptman J , Boldrin MN , et al.   XENical in the prevention of diabetes in obese subjects (XENDOS) study (a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients) . Diabetes Care . 2004;27:155–161
  334. Yusuf S , Sleight P , Pogue J , et al.  The Heart Outcomes Prevention Evaluation Study Investigators   Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients . N Engl J Med . 2000;342:145–153
  335. Yusuf S , Gerstein H , Hoogwerf B , et al.   Ramipril and the development of diabetes . JAMA . 2001;286:1882–1885
  336. Dahlof B , Devereux RB , Kjeldsen SE , et al.   Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) (a randomised trial against atenolol) . Lancet . 2002;359:995–1003
  337. Lindholm LH , Ibsen H , Dahlof B , et al.   Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) (a randomised trial against atenolol) . Lancet . 2002;359:1004–1010
  338. Julius S , Kjeldsen SE , Weber M , et al.   Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine (the VALUE randomised trial) . Lancet . 2004;363:2022–2031
  339. Krutzfeldt J , Raasch W , Klein HH . Ramipril increases the protein level of skeletal muscle IRS-1 and alters protein tyrosine phosphatase activity in spontaneously hypertensive rats . Naunyn Schmiedebergs Arch Pharmacol . 2000;362:1–6
  340. Iyer SN , Katovich MJ . Effect of acute and chronic losartan treatment on glucose tolerance and insulin sensitivity in fructose-fed rats . Am J Hypertens . 1996;9:662–668
  341. Iyer SN , Raizada MK , Katovich MJ . AT1 receptor density changes during development of hypertension in hyperinsulinemic rats . Clin Exp Hypertens . 1996;18:793–810
  342. Ortlepp JR , Breuer J , Eitner F , et al.   Inhibition of the renin-angiotensin system ameliorates genetically determined hyperinsulinemia . Eur J Pharmacol . 2002;436:145–150
  343. Prasad A , Tupas-Habib T , Schenke WH , et al.   Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis . Circulation . 2000;101:2349–2354
  344. The WOSCOPS Study Group . West of Scotland Coronary Prevention Study: implications for clinical practice. The WOSCOPS Study Group . Eur Heart J . 1996;17:163–164
  345. Heymsfield SB , Segal KR , Hauptman J , et al.   Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults . Arch Intern Med . 2000;160:1321–1326
  346. Schneider R , Golzman B , Turkot S , et al.   Effect of weight loss on blood pressure, arterial compliance, and insulin resistance in normotensive obese subjects . Am J Med Sci . 2005;330:157–160
  347. Yesilbursa D , Serdar A , Heper Y , et al.   The effect of orlistat-induced weight loss on interleukin-6 and C-reactive protein levels in obese subjects . Acta Cardiol . 2005;60:265–269
  348. Chanoine JP , Hampl S , Jensen C , et al.   Effect of orlistat on weight and body composition in obese adolescents (a randomized controlled trial) . JAMA . 2005;293:2873–2883
  349. Filippatos TD , Kiortsis DN , Liberopoulos EN , et al.   Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome (the FenOrli study) . Curr Med Res Opin . 2005;21:1997–2006
  350. Tong NW , Ran XW , Li QF , et al.   [Effects of sibutramine on blood glucose and lipids, body fat mass and insulin resistance in obese patients (a multi-center clinical trial]) . Zhonghua Nei Ke Za Zhi . 2005;44:659–663
  351. Faria AN , Ribeiro Filho FF , Kohlmann NE , et al.   Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients . Diabetes Obes Metab . 2005;7:246–253
  352. Tankova T , Dakovska G , Lazarova M , et al.   Sibutramine in the treatment of obesity in type 2 diabetic patients and in nondiabetic subjects . Acta Diabetol . 2004;41:146–153
  353. de Simone G , Romano C , De Caprio C , et al.   Effects of sibutramine-induced weight loss on cardiovascular system in obese subjects . Nutr Metab Cardiovasc Dis . 2005;15:24–30
  354. Despres JP , Golay A , Sjostrom L . Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia . N Engl J Med . 2005;353:2121–2134
  355. Van Gaal LF , Rissanen AM , Scheen AJ , et al.   Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients (1-year experience from the RIO-Europe study) . Lancet . 2005;365:1389–1397
  356. Dixon JB , O’Brien PE . Health outcomes of severely obese type 2 diabetic subjects 1 year after laparoscopic adjustable gastric banding . Diabetes Care . 2002;25:358–363
  357. Pontiroli AE , Folli F , Paganelli M , et al.   Laparoscopic gastric banding prevents type 2 diabetes and arterial hypertension and induces their remission in morbid obesity (a 4-year case-controlled study) . Diabetes Care . 2005;28:2703–2709
  358. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group . Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic (The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)) . JAMA . 2002;288:2981–2997
  359. Rubins HB , Robins SJ , Collins D , et al.  Department of Veterans Affairs HDL Intervention Trial Study Group   Distribution of lipids in 8,500 men with coronary artery disease . Am J Cardiol . 1995;75:1196–1201
  360. Mosca L , Merz NB , Blumenthal RS , et al.   Opportunity for intervention to achieve American Heart Association guidelines for optimal lipid levels in high-risk women in a managed care setting . Circulation . 2005;111:488–493
  361. NCEP Expert Panel on the Detection and Treatment of High Blood Cholesterol in Adults (ATP III) . Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report . Circulation . 2002;106:3143–3421
  362. Grundy SM , Cleeman JI , Merz CN , et al.   Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines . Circulation . 2004;110:227–239
  363. Ericsson CG , Nilsson J , Grip L , et al.   Effect of bezafibrate treatment over five years on coronary plaques causing 20% to 50% diameter narrowing (The Bezafibrate Coronary Atherosclerosis Intervention Trial [BECAIT]) . Am J Cardiol . 1997;80:1125–1129
  364. Elkeles RS , Diamond JR , Poulter C , et al.   Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary’s, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study . Diabetes Care . 1998;21:641–648
  365. Meade T , Zuhrie R , Cook C , et al.   Bezafibrate in men with lower extremity arterial disease (randomised controlled trial) . BMJ . 2002;325:1139
  366. Frick MH , Elo O , Haapa K , et al.   Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease . N Engl J Med . 1987;317:1237–1245
  367. Rubins HB , Robins SJ , Collins D , et al.  Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group   Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol . N Engl J Med . 1999;341:410–418
  368. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes (the Diabetes Atherosclerosis Intervention Study, a randomised study) . Lancet . 2001;357:905–910
  369. Tenenbaum A , Motro M , Fisman EZ , et al.   Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome . Arch Intern Med . 2005;165:1154–1160
  370. Koh KK , Han SH , Quon MJ , et al.   Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia . Diabetes Care . 2005;28:1419–1424
  371. Grundy SM , Hansen B , Smith SC , et al.   Clinical management of metabolic syndrome (report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management) . Circulation . 2004;109:551–556
  372. Vega GL , Ma PT , Cater NB , et al.   Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome . Am J Cardiol . 2003;91:956–960
  373. Ballantyne CM , Stein EA , Paoletti R , et al.   Efficacy of rosuvastatin 10 mg in patients with the metabolic syndrome . Am J Cardiol . 2003;91:25C–27C discussion 28C.
  374. Deedwania PC , Hunninghake DB , Bays HE , et al.   Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome . Am J Cardiol . 2005;95:360–366
  375. Knopp RH , Alagona P , Davidson M , et al.   Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia . Metabolism . 1998;47:1097–1104
  376. Goldberg AC . Clinical trial experience with extended-release niacin (Niaspan) (dose-escalation study) . Am J Cardiol . 1998;82:35U–38U discussion 39U-41U.
  377. McKenney JM , McCormick LS , Schaefer EJ , et al.   Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia . Am J Cardiol . 2001;88:270–274
  378. Zambon A , Hokanson JE , Brown BG , et al.   Evidence for a new pathophysiological mechanism for coronary artery disease regression (hepatic lipase-mediated changes in LDL density) . Circulation . 1999;99:1959–1964
  379. Miller BD , Alderman EL , Haskell WL , et al.   Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project . Circulation . 1996;94:2146–2153
  380. Stampfer MJ , Krauss RM , Ma J , et al.   A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction . JAMA . 1996;276:882–888
  381. Shepherd J , Betteridge J , Van Gaal L . Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome (a position paper developed by a European Consensus Panel) . Curr Med Res Opin . 2005;21:665–682
  382. Khan BV , Sola S , Lauten WB , et al.   Quinapril, an ACE inhibitor, reduces markers of oxidative stress in the metabolic syndrome . Diabetes Care . 2004;27:1712–1715
  383. Wakino S , Kintscher U , Kim S , et al.   Peroxisome proliferator-activated receptor gamma ligands inhibit retinoblastoma phosphorylation and G1 → S transition in vascular smooth muscle cells . J Biol Chem . 2000;275:22435–22441
  384. Xiang AH , Peters RK , Kjos SL , et al.   Effect of thiazolidinedione treatment on progression of subclinical atherosclerosis in premenopausal women at high risk for type 2 diabetes . J Clin Endocrinol Metab . 2005;90:1986–1991
  385. Hetzel J , Balletshofer B , Rittig K , et al.   Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers . Arterioscler Thromb Vasc Biol . 2005;25:1804–1809
  386. Szapary PO , Bloedon LT , Samaha FF , et al.   Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome . Arterioscler Thromb Vasc Biol . 2006;26:182–188
  387. Marx N , Wohrle J , Nusser T , et al.   Pioglitazone reduces neointima volume after coronary stent implantation (a randomized, placebo-controlled, double-blind trial in nondiabetic patients) . Circulation . 2005;112:2792–2798
  388. Sola S , Mir MQ , Cheema FA , et al.   Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome (results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study) . Circulation . 2005;111:343–348
  389. Pearson TA , Blair SN , Daniels SR , et al.  American Heart Association Science Advisory and Coordinating Committee   AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases . Circulation . 2002;106:388–391
  390. Caldwell SH , Hespenheide EE , Redick JA , et al.   A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis . Am J Gastroenterol . 2001;96:519–525
  391. Neuschwander-Tetri BA , Brunt EM , Wehmeier KR , et al.   Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone . Hepatology . 2003;38:1008–1017
  392. Shadid S , Jensen MD . Effect of pioglitazone on biochemical indices of non-alcoholic fatty liver disease in upper body obesity . Clin Gastroenterol Hepatol . 2003;1:384–387
  393. Setola E , Monti LD , Galluccio E , et al.   Insulin resistance and endothelial function are improved after folate and vitamin B12 therapy in patients with metabolic syndrome (relationship between homocysteine levels and hyperinsulinemia) . Eur J Endocrinol . 2004;151:483–489
  394. Shulman AI , Mangelsdorf DJ . Retinoid x receptor heterodimers in the metabolic syndrome . N Engl J Med . 2005;353:604–615
  395. Luquet S , Gaudel C , Holst D , et al.   Roles of PPAR delta in lipid absorption and metabolism (a new target for the treatment of type 2 diabetes) . Biochim Biophys Acta . 2005;1740:313–317

PII: S0011-5029(06)00024-1

doi: 10.1016/j.disamonth.2006.03.001

Disease-A-Month
Volume 52, Issue 2 , Pages 55-144 , February 2006

Article Tools

* Image Usage & Resolution